EP2841072A4 - Combination meloxicam and xylazine therapy in animals - Google Patents

Combination meloxicam and xylazine therapy in animals

Info

Publication number: EP2841072A4
Authority: EP; European Patent Office
Prior art keywords: meloxicam; xylazine; animals; therapy; combination
Prior art date: 2012-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP13781843.1A

Other languages

German (de)

French (fr)

Other versions

EP2841072A1 (en

Inventor

Guiseppe Pippia

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

TROY LABORATORIES Pty Ltd

TROY LAB Pty Ltd

Original Assignee

TROY LABORATORIES Pty Ltd

TROY LAB Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-27

Filing date

2013-04-26

Publication date

2016-01-06

2012-04-27 Priority claimed from AU2012901666A external-priority patent/AU2012901666A0/en

2013-04-26 Application filed by TROY LABORATORIES Pty Ltd, TROY LAB Pty Ltd filed Critical TROY LABORATORIES Pty Ltd

2015-03-04 Publication of EP2841072A1 publication Critical patent/EP2841072A1/en

2016-01-06 Publication of EP2841072A4 publication Critical patent/EP2841072A4/en

Status Withdrawn legal-status Critical Current

Links

241001465754 Metazoa Species 0.000 title 1
229940038665 combination meloxicam Drugs 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 title 1
229960001600 xylazine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Rheumatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Anesthesiology (AREA)
Neurosurgery (AREA)
Dispersion Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP13781843.1A 2012-04-27 2013-04-26 Combination meloxicam and xylazine therapy in animals Withdrawn EP2841072A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AU2012901666A AU2012901666A0 (en)		2012-04-27	Combination of meloxicam and xylazine therapy in animals
PCT/AU2013/000429 WO2013159151A1 (en)	2012-04-27	2013-04-26	Combination meloxicam and xylazine therapy in animals

Publications (2)

Publication Number	Publication Date
EP2841072A1 EP2841072A1 (en)	2015-03-04
EP2841072A4 true EP2841072A4 (en)	2016-01-06

Family

ID=49482035

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP13781843.1A Withdrawn EP2841072A4 (en)	2012-04-27	2013-04-26	Combination meloxicam and xylazine therapy in animals

Country Status (4)

Country	Link
EP (1)	EP2841072A4 (en)
AU (3)	AU2013252491A1 (en)
NZ (1)	NZ701190A (en)
WO (1)	WO2013159151A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060239928A1 (en) *	2005-02-17	2006-10-26	Heit Mark C	Transmucosal administration of drug compositions for treating and preventing disorders in animals
WO2012009542A2 (en) *	2010-07-14	2012-01-19	Kansas State University Research Foundation	Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUT47849A (en) *	1986-11-03	1989-04-28	Sandoz Ag	Process for producing new pharmaceutical with analgetic and hypertonicity-relaxing effect
WO2007072503A2 (en) *	2005-12-21	2007-06-28	Panacea Biotec Ltd.	Combinations for managing inflammation and associated disorders
AR073435A1 (en) *	2006-10-18	2010-11-10	Senosiain S A De C V Lab	PHARMACEUTICAL COMPOSITION OF MODIFIED RELEASE OF A RELAXING MUSCLE AND AN NSAID
EP2329849B1 (en) *	2009-11-18	2015-04-29	Galderma Research & Development	Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder

2013
- 2013-04-26 WO PCT/AU2013/000429 patent/WO2013159151A1/en not_active Ceased
- 2013-04-26 EP EP13781843.1A patent/EP2841072A4/en not_active Withdrawn
- 2013-04-26 AU AU2013252491A patent/AU2013252491A1/en not_active Abandoned
- 2013-04-26 NZ NZ701190A patent/NZ701190A/en unknown
2017
- 2017-08-10 AU AU2017101084A patent/AU2017101084B4/en not_active Ceased
2018
- 2018-02-12 AU AU2018201002A patent/AU2018201002A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060239928A1 (en) *	2005-02-17	2006-10-26	Heit Mark C	Transmucosal administration of drug compositions for treating and preventing disorders in animals
WO2012009542A2 (en) *	2010-07-14	2012-01-19	Kansas State University Research Foundation	Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Xylazine Hydrochloride", THE EUROPEAN AGENCY FOR THE EVALUATION OF MEDICINAL PRODUCTS - VETERINARY MEDICINES EVALUATION UNIT, June 1999 (1999-06-01), pages 1 - 5, XP055230480, Retrieved from the Internet <URL:http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500015345.pdf> [retrieved on 20151123] *
JAIN N K ET AL: "Modulation of NSAID-induced antinociceptive and anti-inflammatory effects by alpha2-adrenoceptor agonists with gastroprotective effects", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 70, 2002, pages 2857 - 2869, XP003024888, ISSN: 0024-3205, DOI: 10.1016/S0024-3205(02)01549-7 *
See also references of WO2013159151A1 *

Also Published As

Publication number	Publication date
AU2017101084B4 (en)	2017-11-02
AU2017101084A4 (en)	2017-09-07
AU2013252491A1 (en)	2014-11-06
WO2013159151A1 (en)	2013-10-31
EP2841072A1 (en)	2015-03-04
NZ701190A (en)	2016-07-29
AU2018201002A1 (en)	2018-03-01

Legal Events

Date	Code	Title	Description
2015-01-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2015-03-04	17P	Request for examination filed	Effective date: 20141024
2015-03-04	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2015-03-04	AX	Request for extension of the european patent	Extension state: BA ME
2015-08-05	DAX	Request for extension of the european patent (deleted)
2016-01-06	RA4	Supplementary search report drawn up and despatched (corrected)	Effective date: 20151207
2016-01-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/10 20060101ALI20151201BHEP Ipc: A61P 29/00 20060101ALI20151201BHEP Ipc: A61K 31/5415 20060101AFI20151201BHEP Ipc: A61K 9/06 20060101ALI20151201BHEP Ipc: A61K 47/02 20060101ALI20151201BHEP Ipc: A61K 31/54 20060101ALI20151201BHEP Ipc: A61K 9/00 20060101ALI20151201BHEP Ipc: A61P 25/20 20060101ALI20151201BHEP
2016-12-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2017-01-18	18D	Application deemed to be withdrawn	Effective date: 20160715

Publication	Publication Date	Title
ZA201406969B (en)	2020-01-29	Combination therapy with an anti-hyaluronan agent and a tumor-targreted taxane
GB201218862D0 (en)	2012-12-05	Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en)	2012-12-05	Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en)	2012-12-05	Bicyclic heterocycle compounds and their uses in therapy
IL234794A0 (en)	2014-12-31	Cold therapy device
EP2867209A4 (en)	2015-11-25	Compounds and therapeutic uses thereof
GB201216649D0 (en)	2012-10-31	Agents and methods
NL301064I2 (en)	2021-03-03	toltrazuril and gleptoferron
ZA201504405B (en)	2016-11-30	6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
IL233652A0 (en)	2014-08-31	Substituted phenylimidazopyrazoles and use thereof
IL238174A0 (en)	2015-05-31	Combination therapy with volasertib
GB201308753D0 (en)	2013-06-26	Compounds and their use in therapy
EP2841072A4 (en)	2016-01-06	Combination meloxicam and xylazine therapy in animals
GB201308217D0 (en)	2013-06-12	Compounds and their use in therapy
GB201322869D0 (en)	2014-02-12	Therapeutic agents and delivery with microspheres
AU2012901666A0 (en)	2012-05-10	Combination of meloxicam and xylazine therapy in animals
HUE048382T2 (en)	2020-07-28	6-chloro-3-(phenyl-d5)-inden-1-one and use thereof
AU2010900863A0 (en)	2010-03-18	Combination meloxicam and xylazine therapy in animals
GB201102213D0 (en)	2011-03-23	Inventions and therapy
GB201102232D0 (en)	2011-03-23	Inventions and therapy
GB201102239D0 (en)	2011-03-23	Inventions and therapy
GB201102226D0 (en)	2011-03-23	Inventions and therapy
GB201102221D0 (en)	2011-03-23	Inventions and therapy
GB201102216D0 (en)	2011-03-23	Inventions and therapy
GB201102215D0 (en)	2011-03-23	Inventions and therapy